Dec 30, 2025 • AD HOC NEWS
SOMEWHAT-BULLISH
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook
Exact Sciences Corp. is transforming cancer screening into a software-driven diagnostics platform, making early detection more routine. The company is known for its Cologuard at-home colon cancer screening test and has expanded into multi-cancer early detection and precision oncology. Their strategy focuses on noninvasive screening, precision oncology tools like Oncotype DX, and developing multi-cancer early detection (MCED) via a data-driven approach, positioning them as a critical infrastructure in cancer care.
Dec 29, 2025 • Investing.com
NEUTRAL
Exact Sciences accelerates executive bonuses and equity awards ahead of merger
Exact Sciences Corp. announced that its board has approved accelerated vesting and payment of annual bonuses and equity awards for executive officers. This decision is related to the company's pending merger with Abbott Laboratories and aims to address potential tax implications under Sections 280G and 4999 of the Internal Revenue Code. The move also outlines specific accelerated payments for key executives and details regarding annual bonuses, RSU, and PSU awards, along with clawback provisions.
Dec 28, 2025 • MarketBeat
NEUTRAL
Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS
Harbor Capital Advisors Inc. significantly reduced its stake in Exact Sciences Corporation by selling 29,990 shares, decreasing its holdings by 61.6% to 18,705 shares. This comes amidst mixed analyst ratings, with a current consensus of "Hold" and a price target of $85, despite Exact Sciences beating Q3 earnings and revenue estimates. Insider selling has also been reported, with executives and directors offloading shares.
Dec 25, 2025 • MarketBeat
NEUTRAL
Exact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Hold" by Analysts
Exact Sciences Corporation (NASDAQ:EXAS) has received a consensus "Hold" rating from analysts, with an average 1-year price target of $85.00, despite some recent downgrades and upgrades. The company exceeded quarterly earnings and revenue estimates but remains unprofitable with a negative net margin. Shares are trading near their 52-week high, with significant institutional ownership and recent insider share sales.
Dec 19, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
Is Exact Sciences Stock Still Attractive After a 78.1% Surge in 2025?
Exact Sciences (EXAS) stock has surged 78.1% in 2025, driven by its expanding cancer screening franchise. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is fairly valued at around $105.37 per share, indicating most long-term growth is already priced in. However, its Price-to-Sales (P/S) ratio of 6.24x is below the Biotech industry average, suggesting a potential mild discount on this metric.
Dec 12, 2025 • Business Wire
BULLISH
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
Exact Sciences, in collaboration with the NSABP Foundation and the German Breast Group, announced positive clinical study results for its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC). The study, presented at SABCS, showed that the Oncodetect test powerfully predicts distant recurrence after surgery in TNBC patients. The data highlights the test's potential to guide post-surgical treatment decisions and identify high-risk patients.